BARCELONA, Nov. 10, 2022 /PRNewswire/ — REVEAL GENOMICS, S.L., a biotechnological start-up dedicated to revolutionizing precision oncology through biomarker innovation, has announced the inclusion of HER2DX® in TIME’s list of “Best inventions of 2022”.
The list, which is drawn up every year and made public today, includes those inventions that the publication considers “make the world better, smarter and even more fun”, according to its own definition.
The HER2DX® has been named as one of the best inventions in the “Medical Care” category, which are those innovations used in medical consultations and hospitals that provide effective responses to patients.
On HER2DX®, the publication comments: “The test favors better results for early-stage patients, but could also lead to more personalized approaches for advanced-stage breast cancers.”
For Dr. Patricia Villagrasa, C0-founder and CEO of REVEAL GENOMICS®, TIME’s recognition “endorses our first product and drives us to continue with our vision of the future of precision oncology. We created REVEAL GENOMICS® to develop unique solutions with proven clinical utility, and HER2DX® exemplifies our potential. The immediate goal of REVEAL GENOMICS® is to ensure that HER2DX® is globally available and reaches all HER2 breast cancer patients.”
Dr. Aleix Prat, Co-founder and CSO of REVEAL GENOMICS®, comments: “HER2 breast cancer is a health problem that affects more than 400,000 women a year. To date, we did not have any tools to help the oncologist and the patient make key therapeutic decisions for her life.
Consequently, many patients experienced overtreatment or undertreatment. For this reason, we developed HER2DX®, the first test that helps optimize treatment for this type of patient.”
The best inventions of the year, TIME’s annual appointment This year, TIME has recognized those inventions that have reached important milestones between November 2021 and September 2022, as is the case of HER2DX® with its introduction to the market in January of this year .
To create the list, TIME solicits nominations from its editors and correspondents around the world, and also enables online nominations. Once the applications have been collected, the publication evaluates each of the inventions in aspects such as impact, originality, creativity and effectiveness.
The full list of honorees appears in the print publication and on TIME’s website (with a global audience of 100 million people), as well as on the publication’s social media channels including Twitter (18 million followers), Facebook ( 13 million fans) and Instagram (11 million followers) and generates an estimated 650 million media impressions worldwide.
About HER2DX® HER2DX® is the world’s first diagnostic test created specifically for HER2 breast cancer. Marketed by REVEAL GENOMICS® since January 2022, the HER2DX® is a standardized 27-gene expression test for patients with early-stage HER2 breast cancer.
HER2DX® provides a prognostic and predictive report based on clinical and genomic data. The test integrates clinical information (tumor size and node status) with biological information (immune infiltration, luminal differentiation, tumor cell proliferation, and expression of the HER2 chromosomal amplicon 17q12-21, including the ERBB2 gene).
HER2DX® provides
About REVEAL GENOMICS®REVEAL GENOMICS, S.L. is a biotech start-up that seeks to change the way biomarkers are used in oncology. It focuses on the development of innovative diagnostic tools to define the best therapeutic options for cancer patients. The company uses pioneering techniques, sophisticated computer applications and machine learning to uncover new research data about cancer.
REVEAL GENOMICS® is a spin-off of Hospital Clínic de Barcelona, IDIBAPS, the University of Barcelona (U.B.) and the Vall d’Hebrón Institute of Oncology (VHIO).
REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS, S.L.
Web: www.reveal-genomics.com. Twitter: @revealgenomics
For more information: Adriana Herrera, aherrera@reveal-genomics.com
logo – link
View original content: enlace
